"What I don’t understand is how there hasn’t b
Post# of 148166
That happens when you over-enroll open-label, non-randomized studies by 300% or more, and fail to conduct appropriate studies...
FDA should have asked to stop enrollment in those trials (similar to what they did with our eINDs) and asked for double-blind, placebo-controlled studies...